The U.S. Food and Drug Administration (FDA) has accepted Travere Therapeutics’ (NASDAQ:TVTX) New Drug Application (NDA) under Subpart H and granted Priority Review of sparsentan for the treatment of IgA nephropathy (IgAN).
The regulatory agency has assigned a Prescription Drug User Fee Act (PDUFA) target action date of November 17, 2022.
